Knowledge Gaps in the Treatment of Carcinoid Syndrome

Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symptoms of carcinoid syndrome can negatively impact patients' quality of life and functioning. Baseline data collected from a continuing nursing education (CNE)-approved Oncology Nursing Strategy Session titled Optimizing Management of Carcinoid Syndrom...
Continue reading

Predicting Relapse in Pancreatic Neuroendocrine Tumors

Researchers have found a new way to classify non-functional pancreatic neuroendocrine tumors (PNETs) in order to predict which patients will experience relapse. Most PNETs are non-functional, meaning that they do not release excess hormones into the bloodstream. In current practice, patients whose non-functional PNETs are larger than 2 cm are considered at the highest risk of metastatic recurrence following surgery. "As clinical behaviors [of non-functional PNETs] vary widely and distant metasta...
Continue reading

Metastatic Merkel Cell Carcinoma: Treatment Challenges and Best Practices With Paul Nghiem, MD, PhD

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 1,500 cases are diagnosed in the United States annually. The rapid rise of MCC incidence during the past few decades has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin and warrants further research. Treatment standards are ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.